Skip to main content
NCBI home page
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2012 Mar 2;287(16):13457–13464. doi: 10.1074/jbc.M111.268185

Sphingosine 1-Phosphate (S1P) Regulates Glucose-stimulated Insulin Secretion in Pancreatic Beta Cells*

Jamie Cantrell Stanford ‡, Andrew J Morris §, Manjula Sunkara §, Gabriel J Popa ‡, Kara L Larson ‡, Sabire Özcan ‡,1
PMCID: PMC3339968  PMID: 22389505

Background: Sphingolipids play an important role in glucose homeostasis.

Results: High glucose induces SphK activity, leading to increases in S1P levels and stimulation of insulin secretion.

Conclusion: SphK activity and S1P levels are critical for glucose-stimulated insulin secretion.

Significance: The presented data uncover a new role for SphK and S1P in regulation of insulin secretion by glucose.

Keywords: Beta Cell, Diabetes, Glucose, Insulin Secretion, sphingosine 1-phosphate, SphK2, Sphingosine Kinase, Sphingosine Kinase Inhibitor

Abstract

Recent studies suggest that sphingolipid metabolism is altered during type 2 diabetes. Increased levels of the sphingolipid ceramide are associated with insulin resistance. However, a role for sphingolipids in pancreatic beta cell function, or insulin production, and release remains to be established. Our studies in MIN6 cells and mouse pancreatic islets demonstrate that glucose stimulates an intracellular rise in the sphingolipid, sphingosine 1-phosphate (S1P), whereas the levels of ceramide and sphingomyelin remain unchanged. The increase in S1P levels by glucose is due to activation of sphingosine kinase 2 (SphK2). Interestingly, rises in S1P correlate with increased glucose-stimulated insulin secretion (GSIS). Decreasing S1P levels by treatment of MIN6 cells or primary islets with the sphingosine kinase inhibitor reduces GSIS. Moreover, knockdown of SphK2 alone results in decreased GSIS, whereas knockdown of the S1P phosphatase, Sgpp1, leads to a rise in GSIS. Treatment of mice with the sphingosine kinase inhibitor impairs glucose disposal due to decreased plasma insulin levels. Altogether, our data suggest that glucose activates SphK2 in pancreatic beta cells leading to a rise in S1P levels, which is important for GSIS.

Introduction

The onset and progression of type II diabetes have been linked to alterations in sphingolipid metabolism (1–4). Studies show that ceramide levels are significantly increased in the blood, muscle, liver, and adipose tissue of diabetic rodents and humans (1, 5–7). Increased levels of ceramide correlate with increased insulin resistance, suggesting that ceramide plays an important role in promoting insulin resistance (1, 2, 4, 7). Consistent with this idea, inhibition of ceramide synthesis enhances insulin sensitivity (8–10). Recent data indicate that ceramide may also inhibit insulin gene transcription in pancreatic beta cells under diabetic conditions (11, 12). In addition, ceramide, which is known to induce apoptosis in many cell types, has been shown to mimic cytokine-induced beta cell death (13, 14).

The sphingolipid, sphingosine 1-phosphate (S1P),2 which opposes the actions of ceramide, also has an effect on beta cell function. S1P protects beta cells from cytokine-induced cell death (14). S1P may also have a role in insulin secretion. Exogenously added S1P promotes insulin secretion in HIT-T15 cells and mouse pancreatic islets (15). S1P acts as a signaling molecule by binding both extracellular and intracellular targets (16, 17). Extracellular targets include the five known S1P receptors, S1P1–5, four of which (S1P1–4) are expressed in the rat pancreatic INS1 cell line and mouse pancreatic islets (18). S1P receptors are G protein-coupled receptors; therefore, upon S1P binding, many downstream signaling pathways are activated, including PI3K/Akt, Ras/Erk, PLC, Rho, Rac, and adenylate cyclase (16). The intracellular targets of S1P are largely unknown. However, a recent study discovered that intracellular S1P inhibits HDAC1/HDAC2 activity and thereby regulates histone acetylation and gene transcription (19).

S1P is synthesized by phosphorylation of sphingosine via sphingosine kinases (SphKs). There are two sphingosine kinase isoforms, SphK1 and SphK2 (20–22). SphK1 has been shown to have a role in insulin signaling and in maintaining glucose homeostasis. Specifically, overexpression of SphK1 in KK/Ay diabetic mice leads to decreases in blood glucose levels (23). In addition, high glucose conditions stimulate SphK1 activity in endothelial cells (24). In support of the idea that S1P may be involved in promoting beta cell viability, SphK activity is increased in the presence of cytokines in INS-1 cells and mouse pancreatic islets (14). Furthermore, of the two isoforms, SphK2 appears to be the dominant active isoform in pancreatic beta cells (25). There are two isoforms of sphingosine-1-phosphate phosphatases, Sgpp1 and Sgpp2, that dephosphorylate S1P to sphingosine (20). To date, neither isoform has been directly implicated in contributing to diabetes.

In this study, we investigated the role of S1P in pancreatic beta cell function and discovered that exposure to high glucose increases S1P levels by activation of sphingosine kinase isoform 2. Furthermore, we demonstrate that the increase in S1P level is important for glucose-stimulated insulin secretion.

EXPERIMENTAL PROCEDURES

Animals

C57BL6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed at the University of Kentucky Animal Facility. All experiments carried out with animals were performed according to protocols approved by the University of Kentucky Institutional Animal Care and Use Committee (IACUC).

Cell Culture

Mouse insulinoma-6 (MIN6) cell line was maintained as described previously (26). Experiments were performed using MIN6 cells grown to passages 22–30.

Insulin Enzyme-linked Immunosorbent Assay (ELISA)

ELISA was carried out according to the manufacturer's specifications (Mercodia Inc.). All insulin secretion assays were run in duplicates, and results were expressed as -fold differences (1 mm glucose control = 1-fold) in secreted insulin. Insulin levels were normalized to total protein.

Glucose Tolerance Test

Mice were i.p. injected with DMSO or sphingosine kinase inhibitor (SKI) (65 mg/kg) followed by a 4-h starvation period. After starvation, 2 g of glucose/kg of body weight was i.p. injected. Blood glucose (mg/dl) was measured every 15 min up to 120 min. Blood samples were collected to measure insulin levels using the insulin ELISA.

Insulin Secretion Assay

Cells were washed with 1× PBS and preincubated on DMEM with 1 mm glucose for 16 h. Following this incubation, cells were incubated with freshly made KRBB containing 1 mm glucose for 2 h. For experiments performed with SKI (Calbiochem), cells were incubated with 1 mm glucose in KRBB for 1.5 h followed by a 30-min incubation on KRBB with 1 mm glucose with or without 10 μm SKI or DMSO. Following preincubations, cells were incubated in KRBB with 1 or 25 mm glucose for 1 h, at the end of which supernatant was collected and insulin was quantified using ELISA. Insulin secretion in purified islets was assayed by pretreatment of 50 purified islets with KRBB buffer containing 3 mm glucose with or without 40 μm SKI or DMSO for 1h. After the pretreatment, islets were transferred into KRBB buffer containing 3 or 20 mm glucose with or without SKI (40uM) for 1 h, and the amount of secreted insulin was quantified using the insulin ELISA assay.

In Vitro Sphingosine Kinase Assay

The sphingosine kinase assay is a modification of a previously described assay (27) and was carried out using the assay buffer (50 mm HEPES, pH 7.4, 150 mm NaCl, 5 mm MgCl2, 1 mm DTT, and 3 μm sodium orthovanadate) with 1 mm ATP, 20 μm C17 sphingosine, 10 μm C18 S1P (internal standard), and cell lysate at 37 °C for the indicated times. The reaction was stopped by adding 0.4 ml of 0.1 m HCl. Lipids were extracted and quantified using LC-MS/MS.

Lipid Extraction and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Sphingolipids were extracted and quantified as described previously (28). Extracted lipids were quantified using the Applied Biosystems 4000 Q-Trap mass spectrometer. The obtained data were normalized to lipid recovery, using the C17 S1P control, and to total starting material, using lipid PO4.

Pancreatic Islet Isolation

Pancreatic islets were isolated from C57BL6 mice. Pancreata were removed aseptically via bile duct injection of Hanks' balanced salt solution (Invitrogen) containing 0.5 mg/ml collagenase type V (Sigma) and incubated at 37 °C. Collagenase digestion was stopped by adding chilled Hanks' balanced salt solution with 10% fetal calf serum. Islets were purified using a Histopaque gradient (Histopaque-1077, Sigma). The purified islets were incubated in RPMI 1640 with 10% FBS. Islets were handpicked into KRBB and transferred to low (3 mm) or high (20 mm) glucose in KRBB for the indicated time points.

siRNA Knockdown

siRNA knockdown experiments were performed as described previously (29, 30). siRNAs were transfected into MIN6 cells using the Amaxa cell line Nucleofector kit V (Lonza) according to the manufacturer's specifications. About 4 μg of siRNA per 1.0 × 10−6 cells was used to achieve optimal knockdown. The sequence of the siRNAs is listed in supplemental Table 1.

Quantitative Real-time Polymerase Chain Reaction

Quantitative real-time PCR was performed as described previously (29, 30). Quantitative real-time-PCR was carried out using the Mx4000 machine (Stratagene) with primers for Sgpp1 (5′-TGGGAGCCATTTCCTAGTTG-3′ and 5′-AGCAAACTTCCCCCAAAACT-3′), pre-pro-insulin (5′-GGGGAGCGTGGCTTCTTCTA-3′ and 5′-GGGGACAGAATTCAGTGGCA-3′), and β-actin (5′-CGTGGGCCGCCCTAGGCAACC-3′ and 5′-TTGGCCTTAGGGTTCAGGGGG-3′). For Sphk1 (Mm00448841_g1) and β-actin, TaqMan probes were used.

Western Blotting

Total lysate was prepared from MIN6 cells with standard lysis buffer (50 mm Tris-HCl, pH 7.5, 300 mm NaCl, 0.1% Nonidet P-40, 5 mm EDTA, and protease/phosphatase inhibitors). Western blot analysis of whole cell lysates was conducted as described previously (29, 30, 31). Antibodies used were: SphK1 (Santa Cruz Biotechnology, sc-48825) and SphK2 (Santa Cruz Biotechnology, sc-22704).

Statistical Analysis

The Student's paired t test was used to determine statistical significance. All experiments analyzed for significance were performed at a minimum of three times. A p value < 0.05 was considered statistically significant. Error bars represent ± S.D.

RESULTS

S1P Levels Are Increased under High Glucose Conditions in Pancreatic Beta Cells

Sphingolipid levels are known to be altered in obesity and during type 2 diabetes, indicating that these lipids may be involved in regulating glucose homeostasis. Because the production and secretion of insulin in pancreatic beta cells are regulated by changes in glucose levels, we measured S1P levels in the mouse insulinoma cell line MIN6 after incubation with 1 or 25 mm glucose. Exposure of MIN6 cells to high glucose (25 mm) for 1 h resulted in about 2-fold increase in S1P levels when compared with 1 mm glucose incubated cells (Fig. 1A), whereas there were no significant changes in the levels of other sphingolipids, such as sphingomyelin and ceramide (supplemental Fig. S1). We observed a similar increase in S1P levels in purified mouse pancreatic islets by treatment with 20 mm versus 3 mm glucose (Fig. 1B). These data suggest that S1P levels are regulated by changes in glucose levels in pancreatic beta cells.

FIGURE 1.

FIGURE 1.

Open in a new tab

S1P levels are increased under high glucose conditions. A, S1P levels were quantified in MIN6 cells after incubation in KRBB containing 1 or 25 mm glucose for 1 h. B, S1P levels were quantified in mouse pancreatic islets after incubation in KRBB containing 3 or 20 mm glucose for 1 h. After extraction of lipids from MIN6 cells or islets, S1P levels were quantified using LC-MS/MS. Values were normalized to C17 S1P and total lipid PO4. The results are mean values of three independent experiments (n = 3) ± S.E. *, p < 0.01 versus 1 mm glucose.

High Glucose Stimulates SphK Activity in MIN6 Cells

To determine the mechanism(s) by which glucose mediates changes in S1P levels, we analyzed SphK expression, localization, and activity. Incubation of MIN6 cells with 1 or 25 mm glucose did not alter SphK1 and SphK2 expression, protein stability, or localization (supplemental Figs. S2 and S3). However, we found that SphK activity was increased over 4-fold in MIN6 cells incubated with high glucose (Fig. 2). Previous data indicate that phorbol 12-myristate 13-acetate (PMA) stimulates SphK activity in other cell types (32). Incubation of MIN6 cells with 1 mm glucose in the presence of 100 nm PMA stimulated SphK activity by 8-fold when compared with 1 mm glucose alone (Fig. 2). SphK activity in cell lysates was measured by quantification of newly formed S1P (C17 S1P). The SphK activity assay was not linear, which is likely due to the low level of constitutive degradation of S1P by S1P phosphatases. In summary, exposure of MIN6 cells to high glucose stimulates SphK activity in pancreatic beta cells.

FIGURE 2.

FIGURE 2.

Open in a new tab

Glucose stimulates sphingosine kinase activity in MIN6 cells. Lipids were extracted from MIN6 cells incubated with KRBB containing 1 or 25 mm glucose or 1 mm glucose with 100 nm PMA for 1 h. SphK activity was measured at various time points (0, 10, and 30 min) by quantification of C17 S1P formation by LC-MS/MS. *, p < 0.01; **, p < 0.05 versus 1 mm glucose.

S1P Levels Are Important for GSIS

Because SphK activity is induced by high glucose and S1P levels are significantly increased in the presence of high glucose, we tested whether changes in S1P levels are important for glucose-stimulated insulin secretion (GSIS). First, we blocked the production of S1P using SKI (Fig. 3C). MIN6 cells treated with 10 μm SKI displayed a significant drop in insulin secretion on 25 mm glucose and completely lacked GSIS when compared with untreated cells (Fig. 3A). Treatment of MIN6 cells with SKI did not affect total insulin levels (supplemental Fig. S4). Furthermore, treatment of isolated islets with 40 μm SKI for 1 h significantly diminished GSIS (Fig. 3B). These data suggest that the rise in S1P levels in response to high glucose is important for GSIS. To further substantiate the role of S1P in GSIS in pancreatic beta cells, we either blocked S1P production on high glucose by knockdown of SphKs or increased S1P levels on low glucose by knockdown of Sgpp1. Knockdown of both SphK1 and SphK2 by transfection of MIN6 cells with the corresponding siRNA oligonucleotides completely abolished GSIS (Fig. 4A). Surprisingly, knockdown of SphK1 alone did not have a significant effect on insulin secretion (Fig. 4B), although knockdown of SphK1 reduced overall S1P levels by 30% (Fig. 4D). However, knockdown of SphK2 in MIN6 cells using four different siRNA oligonucleotides reproducibly resulted in complete lack of GSIS when compared with cells transfected with control siRNA (Fig. 4C). Knockdown of SphK2 resulted in a 75% decrease of S1P levels (Fig. 4D). Thus, knockdown of SphK2 completely abolished GSIS. The efficiency of SphK1 and SphK2 knockdown in MIN6 cells was confirmed as shown in supplemental Fig. S5. Knockdown of SphK2 did not affect cell viability when compared with cells transfected with control siRNA (supplemental Fig. S6). In support of an important role for Sphk2 in beta cells, glucose induction of SphK activity was reduced by 6-fold in MIN6 cells transfected with SphK2 siRNAs when compared with control cells (Fig. 5). These data suggest that the increase in S1P levels by high glucose is likely due to activation of SphK2 in the presence of glucose.

FIGURE 3.

FIGURE 3.

Open in a new tab

Inhibition of sphingosine kinase activity decreases GSIS. A, insulin secretion from MIN6 cells incubated with KRBB containing 1 or 25 mm glucose ± SKI for 1 h was measured using insulin ELISA as described under “Experimental Procedures.” B, insulin secretion in pancreatic islets was measured by incubating islets with 3 or 20 mm glucose ± SKI for 1 h. Values are normalized to total insulin and expressed as -fold differences, where 1 mm glucose control (−SKI) was set to 1 (n = 5) ± S.E. *, p < 0.05 versus 25 mm glucose control (−SKI). C, S1P levels were quantified in MIN6 cells treated with KRBB containing 1 mm glucose, 25 mm glucose, or 1 mm glucose plus PMA with or without SKI for 1 h using LC-MS/MS. Values are normalized to total lipid PO4 (n = 5). *, p < 0.05 versus 1 mm, 25 mm glucose control (−SKI), or 1 mm glucose +PMA (−SKI).

FIGURE 4.

FIGURE 4.

Open in a new tab

Knockdown of SphK2 in MIN6 cells abolishes GSIS. A–C, siRNA knockdown was carried out in MIN6 cells using siRNA oligonucleotides, along with control siRNA, targeting both SphK1 and SphK2 (A), only SphK1 (B), and only SphK2 (C). Insulin secretion was assayed in the media after treatment with 1 or 25 mm glucose for 1 h. Values are normalized to total protein and are expressed as -fold differences, with 1 mm glucose control set as 1 (A, n = 3; B, n = 3; C, n = 4) ± S.E. *, p < 0.01 versus 25 mm glucose control. D, S1P levels were quantified in MIN6 cells transfected with siRandom, siSphK1, or siSphhK2 oligonucleotides and incubated on 25 mm glucose. Values are normalized to total lipid PO4 (n = 2).

FIGURE 5.

FIGURE 5.

Open in a new tab

Knockdown of SphK2 abolishes glucose-induced SphK activity. MIN6 cells were transfected with four different SphK2 siRNA or control siRNA oligonucleotides. After incubation for 48 h, cells were treated with KRBB containing 25 mm glucose for 1 h, and protein extracts were prepared. SphK activity was measured at various time points (0, 10, and 30 min) by quantification of C17 S1P formation using LC-MS/MS (n = 3) ± S.E. *, p < 0.05 versus siRandom.

Consistent with a role for S1P in GSIS, knockdown of Sgpp1 did not have any effect on insulin secretion on high glucose, but increased insulin secretion by about 3-fold on low glucose (Fig. 6A). Sgpp1 dephosphorylates S1P to sphingosine, thereby reducing S1P levels in the cells. Knockdown of Sgpp1 resulted in an about 50% increase of S1P levels (Fig. 6B) that led to an increase in insulin secretion (Fig. 6A). The efficiency of Sggp1 knockdown using four different siRNA oligonucleotides was confirmed as illustrated in supplemental Fig. S7.

FIGURE 6.

FIGURE 6.

Open in a new tab

Knockdown of S1P phosphatase Sgpp1 increases insulin secretion on low glucose. A, siRNA knockdown was carried out in MIN6 cells using four different siRNA oligonucleotides targeting Sgpp1 along with control siRNA. Insulin secretion was measured in the media using insulin ELISA and normalized to total protein. Values are expressed as -fold differences, setting 1 mm glucose control as 1 (n = 8) ± S.E. B, S1P levels were quantified in MIN6 cells transfected with siRandom or siSgpp1 oligonucleotides and incubated on 1 mm glucose. Values are normalized to total lipid PO4 (n = 2). *, p < 0.05 versus 1 mm glucose siRandom.

Intraperitoneal Injection of SKI into Mice Impairs Glucose Disposal

Because SKI inhibits GSIS in MIN6 cells, we tested whether SKI treatment of mice affected insulin secretion and thereby glucose disposal during the intraperitoneal glucose tolerance test. For this purpose, 10-week-old C57BL6 mice were i.p. injected with DMSO (control mice) or with 65 mg/kg of body weight of SKI and fasted for 4 h. Following the fasting period, the mice were i.p. injected with 2 g/kg of body weight of glucose and blood glucose, and insulin levels were determined (Fig. 7). Within 30 min after intraperitoneal injection of glucose, the SKI-treated mice had significantly higher blood glucose levels than control mice (Fig. 7, A and B).

FIGURE 7.

FIGURE 7.

Open in a new tab

Mice treated with sphingosine kinase inhibitor SKI have impaired glucose tolerance and decreased plasma insulin levels. 10-week-old C57BL6 mice were injected with DMSO (Control) or 65 mg/kg of body weight of SKI and starved for 4 h. After starvation, the mice were i.p. injected with 2 g/kg of body weight with glucose (intraperitoneal glucose tolerance test), and blood glucose (A and B, Control, n = 6; SKI-treated mice, n = 5) and plasma insulin (C and D, n = 4) levels were monitored every 15 min and quantified using insulin ELISA. *, p < 0.05. AUC, area under the curve.

The glucose intolerance observed in SKI-treated mice correlated with decreased serum insulin levels when compared with control mice (Fig. 7, C and D). Plasma insulin levels in SKI-treated mice were significantly lower than in DMSO-treated control mice (Fig. 7C). The intraperitoneal glucose tolerance test experiments suggest that treatment of mice with the sphingosine kinase inhibitor SKI inhibits insulin secretion and thereby results in impaired glucose disposal.

DISCUSSION

In this study, we have presented evidence that sphingosine kinase activity is regulated by glucose in pancreatic beta cells. Exposure of beta cells to high glucose induces SphK activity, leading to a rise in S1P levels. The increase in S1P levels during high glucose conditions is important for GSIS. Inhibition of S1P production by treatment of cells with the sphingosine kinase inhibitor SKI or by knockdown of SphK2 using siRNAs caused a complete lack of GSIS in pancreatic beta cells. On the other hand, knockdown of Sgpp1, which normally dephosphorylates S1P, led to increased insulin secretion even on low glucose. We conclude from these data that S1P has a novel role in pancreatic beta cells and that changes in S1P levels are important for GSIS.

Although it has previously been reported that exogenously administered S1P to HIT-T15 beta cells stimulates insulin secretion, it was not clear from this previous study whether the addition of exogenous S1P mimicked GSIS (15). Extracellular S1P can function as a signaling molecule by binding to five G protein-coupled S1P receptors, but intracellular S1P can also activate distinct signal pathways (33, 34). We believe that the regulation of GSIS by S1P in pancreatic beta cells involves the activation of intracellular targets of S1P because the rise in S1P coincides with GSIS. Furthermore, we could not detect any extracellular S1P in the medium of MIN6 cells using LC-MS/MS (data not shown).

Regulation of SphK activity and S1P levels by glucose has also been reported previously in endothelial cells (24), suggesting that S1P may play a key role in maintaining glucose homeostasis. Consistent with our data, a recent study also demonstrates that SphK activity is regulated by high glucose in rat pancreatic islets (35).

Knockdown of SphK1 in MIN6 cells had no effect on GSIS. This is interesting considering the fact that knockdown of SphK1 reduced S1P levels by 30% without having an effect on GSIS. It is possible that the overall increase in S1P levels is not important for GSIS, but increases in S1P levels at specific locations or compartments, such as the granules, may be required for GSIS. Knockdown of SphK2 led to a 75% decrease in S1P levels and abolished GSIS in MIN6 cells. This suggests that the observed increase in SphK activity mediated by high glucose is due to activation of SphK2 and that the rise in S1P levels by glucose is likely to be mediated by activation of SphK2. Indeed, knockdown of SphK2 drastically reduced the glucose-induced SphK activity in MIN6 cells (Fig. 5), confirming that the rise in S1P levels on high glucose is mainly due to SphK2 activity. Consistent with this idea, a previous study reported that SphK2 is the major active isoform in pancreatic beta cell lines and rat islets (25).

Although the mechanism(s) by which glucose activates SphK2 in pancreatic beta cells remains to be established, it is most likely that glucose stimulates SphK activity by a post-translational modification. It has been previously shown that PMA induces the phosphorylation and activation of both SphK1 and SphK2 by stimulating the activation of protein kinase C (PKC) and extracellular signal-related kinases 1/2 (ERK1/2) (36–38). These same signaling pathways are also important for glucose-induced beta cell function. Our data show that PMA induces SphK activity on low glucose conditions and that this increase in activity is comparable with that seen on high glucose.

Glucose tolerance experiments in mice indicate that intraperitoneal injection of SKI impairs glucose disposal in mice due to inhibition of insulin secretion. These data suggest that S1P has an important role in GSIS in rodents. Although deletion of SphK1 and SphK2 in mice causes lethality, SphK1 or SphK2 single knock-out mice are viable (39, 40). Neither the SphK1 nor the SphK2 knock-out mice have been reported to be diabetic. Our data presented here suggest that SphK2 activity is essential for GSIS in the MIN6 cell line. Thus, it is expected that mice deleted for SphK2 should have defects in insulin secretion. One explanation for why SphK2 knock-out mice are not diabetic could be that SphK1 compensates for the lack of SphK2. Alternatively, other compensation mechanisms could be active in SphK2 knock-out mice, such as decreased S1P phosphatase activity. However, detailed studies on insulin secretion and glucose disposal in SphK2 knock-out mice are lacking.

Although S1P levels increased during incubation with high glucose within the pancreatic beta cells, the levels of other sphingolipids, including sphingomyelin and ceramide, were not changed. A large body of evidence indicates that chronic hyperglycemia and hyperlipidemia, caused by nutrient excess and diabetes, results in dramatic increases in ceramide levels (1, 5–7, 9). Ceramide and S1P are known to have opposing actions. Typically, when ceramide levels are increased, S1P levels are decreased and vice versa. Therefore, it is likely that under normal conditions, S1P has an important function in pancreatic beta cells and regulates GSIS, but under diabetic conditions, increases in ceramide levels may oppose the actions of S1P, contributing to defects in insulin secretion. Because ceramide appears to negatively affect glucose-stimulated insulin gene transcription, it is possible that it may have the same affect on insulin secretion during diabetes (11). Thus, it would be interesting to determine whether S1P levels are altered within pancreatic islets of diabetic animals, and if so, whether activation of SphK2 within diabetic islets restores impaired GSIS.

In summary, consistent with previous data that indicate an important role for sphingolipids in glucose homeostasis, we demonstrate in this study that changes in S1P levels in pancreatic beta cells impact GSIS. Furthermore, we show that changes in S1P levels are mediated by regulation of SphK2 activity by glucose. Thus, altered S1P levels may interfere with normal glucose homeostasis and contribute to metabolic disorders such as diabetes. Detailed studies on S1P function in pancreatic beta cells may contribute to the development of novel strategies for the treatment of diabetes.

Supplementary Material

Supplemental Data
supp_287_16_13457__index.html (1KB, html)

Acknowledgments

We thank Drs. Robert Dickson, Doug Andres, Kevin Sarge, and Charlotte Kaetzel for helpful input and comments regarding this project.

*

This work was supported, in whole or in part, by National Institutes of Health Grants DK067581 and P20RR020171 (to S. O.). This work was also supported by American Diabetes Association Grant 1-05-CD-15.

2
The abbreviations used are:
S1P
sphingosine 1-phosphate
SphK
sphingosine kinase
GSIS
glucose-stimulated insulin secretion
MIN6
mouse insulinoma 6
SKI
sphingosine kinase inhibitor
Sgpp
sphingosine-1-phosphate phosphatase
KRBB
Krebs-Ringer bicarbonate buffer
PMA
phorbol 12-myristate 13-acetate
DMSO
dimethyl sulfoxide.

REFERENCES

  • 1. Adams J. M., 2nd, Pratipanawatr T., Berria R., Wang E., DeFronzo R. A., Sullards M. C., Mandarino L. J. (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25–31 [DOI] [PubMed] [Google Scholar]
  • 2. Summers S. A. (2010) Sphingolipids and insulin resistance: the five Ws. Curr. Opin. Lipidol. 21, 128–135 [DOI] [PubMed] [Google Scholar]
  • 3. Straczkowski M., Kowalska I. (2008) The role of skeletal muscle sphingolipids in the development of insulin resistance. Rev. Diabet. Stud. 5, 13–24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Straczkowski M., Kowalska I., Baranowski M., Nikolajuk A., Otziomek E., Zabielski P., Adamska A., Blachnio A., Gorski J., Gorska M. (2007) Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 50, 2366–2373 [DOI] [PubMed] [Google Scholar]
  • 5. Haus J. M., Kashyap S. R., Kasumov T., Zhang R., Kelly K. R., Defronzo R. A., Kirwan J. P. (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337–343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Pickersgill L., Litherland G. J., Greenberg A. S., Walker M., Yeaman S. J. (2007) Key role for ceramides in mediating insulin resistance in human muscle cells. J. Biol. Chem. 282, 12583–12589 [DOI] [PubMed] [Google Scholar]
  • 7. Boden G. (2008) Ceramide: a contributor to insulin resistance or an innocent bystander? Diabetologia 51, 1095–1096 [DOI] [PubMed] [Google Scholar]
  • 8. Aerts J. M., Ottenhoff R., Powlson A. S., Grefhorst A., van Eijk M., Dubbelhuis P. F., Aten J., Kuipers F., Serlie M. J., Wennekes T., Sethi J. K., O'Rahilly S., Overkleeft H. S. (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341–1349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Holland W. L., Brozinick J. T., Wang L. P., Hawkins E. D., Sargent K. M., Liu Y., Narra K., Hoehn K. L., Knotts T. A., Siesky A., Nelson D. H., Karathanasis S. K., Fontenot G. K., Birnbaum M. J., Summers S. A. (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 [DOI] [PubMed] [Google Scholar]
  • 10. Zhao H., Przybylska M., Wu I. H., Zhang J., Siegel C., Komarnitsky S., Yew N. S., Cheng S. H. (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210–1218 [DOI] [PubMed] [Google Scholar]
  • 11. Kelpe C. L., Moore P. C., Parazzoli S. D., Wicksteed B., Rhodes C. J., Poitout V. (2003) Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J. Biol. Chem. 278, 30015–30021 [DOI] [PubMed] [Google Scholar]
  • 12. Guo J., Qian Y., Xi X., Hu X., Zhu J., Han X. (2010) Blockage of ceramide metabolism exacerbates palmitate inhibition of pro-insulin gene expression in pancreatic beta cells. Mol. Cell. Biochem. 338, 283–290 [DOI] [PubMed] [Google Scholar]
  • 13. Major C. D., Gao Z. Y., Wolf B. A. (1999) Activation of the sphingomyelinase/ceramide signal transduction pathway in insulin-secreting beta cells: role in cytokine-induced beta cell death. Diabetes 48, 1372–1380 [DOI] [PubMed] [Google Scholar]
  • 14. Laychock S. G., Sessanna S. M., Lin M. H., Mastrandrea L. D. (2006) Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta cells. Endocrinology 147, 4705–4712 [DOI] [PubMed] [Google Scholar]
  • 15. Shimizu H., Okajima F., Kimura T., Ohtani K., Tsuchiya T., Takahashi H., Kuwabara A., Tomura H., Sato K., Mori M. (2000) Sphingosine 1-phosphate stimulates insulin secretion in HIT-T 15 cells and mouse islets. Endocr. J. 47, 261–269 [DOI] [PubMed] [Google Scholar]
  • 16. Kim R. H., Takabe K., Milstien S., Spiegel S. (2009) Export and functions of sphingosine 1-phosphate. Biochim. Biophys. Acta 1791, 692–696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Pyne N. J., Long J. S., Lee S. C., Loveridge C., Gillies L., Pyne S. (2009) New aspects of sphingosine 1-phosphate signaling in mammalian cells. Adv. Enzyme Regul. 49, 214–221 [DOI] [PubMed] [Google Scholar]
  • 18. Laychock S. G., Tian Y., Sessanna S. M. (2003) Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 52, 1986–1993 [DOI] [PubMed] [Google Scholar]
  • 19. Hait N. C., Allegood J., Maceyka M., Strub G. M., Harikumar K. B., Singh S. K., Luo C., Marmorstein R., Kordula T., Milstien S., Spiegel S. (2009) Regulation of histone acetylation in the nucleus by sphingosine 1-phosphate. Science 325, 1254–1257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Pyne S., Lee S. C., Long J., Pyne N. J. (2009) Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signaling in health and disease. Cell. Signal. 21, 14–21 [DOI] [PubMed] [Google Scholar]
  • 21. Taha T. A., Hannun Y. A., Obeid L. M. (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39, 113–131 [DOI] [PubMed] [Google Scholar]
  • 22. Maceyka M., Milstien S., Spiegel S. (2005) Sphingosine kinases, sphingosine 1-phosphate, and sphingolipidomics. Prostaglandins Other Lipid Mediat. 77, 15–22 [DOI] [PubMed] [Google Scholar]
  • 23. Ma M. M., Chen J. L., Wang G. G., Wang H., Lu Y., Li J. F., Yi J., Yuan Y. J., Zhang Q. W., Mi J., Wang L. Sh., Duan H. F., Wu C. T. (2007) Sphingosine kinase 1 participates in insulin signaling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 50, 891–900 [DOI] [PubMed] [Google Scholar]
  • 24. Wang L., Xing X. P., Holmes A., Wadham C., Gamble J. R., Vadas M. A., Xia P. (2005) Activation of the sphingosine kinase signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ. Res. 97, 891–899 [DOI] [PubMed] [Google Scholar]
  • 25. Mastrandrea L. D., Sessanna S. M., Laychock S. G. (2005) Sphingosine kinase activity and sphingosine 1-phosphate production in rat pancreatic islets and INS-1 cells: response to cytokines. Diabetes 54, 1429–1436 [DOI] [PubMed] [Google Scholar]
  • 26. Miyazaki J., Araki K., Yamato E., Ikegami H., Asano T., Shibasaki Y., Oka Y., Yamamura K. (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127, 126–132 [DOI] [PubMed] [Google Scholar]
  • 27. Olivera A., Rosenthal J., Spiegel S. (1996) Effect of acidic phospholipids on sphingosine kinase. J. Cell Biochem. 60, 529–537 [DOI] [PubMed] [Google Scholar]
  • 28. Mathews T. P., Kennedy A. J., Kharel Y., Kennedy P. C., Nicoara O., Sunkara M., Morris A. J., Wamhoff B. R., Lynch K. R., Macdonald T. L. (2010) Discovery, biological evaluation, and structure-activity relationship of amidine-based sphingosine kinase inhibitors. J. Med. Chem. 53, 2766–2778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Andrali S. S., Qian Q., Ozcan S. (2007) Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J. Biol. Chem. 282, 15589–15596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Vanderford N. L., Andrali S. S., Ozcan S. (2007) Glucose induces MafA expression in pancreatic beta cell lines via the hexosamine biosynthetic pathway. J. Biol. Chem. 282, 1577–1584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Vanderford N. L., Cantrell J. E., Popa G. J., Ozcan S. (2008) Multiple kinases regulate mafA expression in the pancreatic beta cell line MIN6. Arch. Biochem. Biophys. 480, 138–142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Buehrer B. M., Bardes E. S., Bell R. M. (1996) Protein kinase C-dependent regulation of human erythroleukemia (HEL) cell sphingosine kinase activity. Biochim. Biophys. Acta 1303, 233–242 [DOI] [PubMed] [Google Scholar]
  • 33. Takabe K., Paugh S. W., Milstien S., Spiegel S. (2008) “Inside-out” signaling of sphingosine 1-phosphate: therapeutic targets. Pharmacol. Rev. 60, 181–195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Rosen H., Gonzalez-Cabrera P. J., Sanna M. G., Brown S. (2009) Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78, 743–768 [DOI] [PubMed] [Google Scholar]
  • 35. Mastrandrea L. D., Sessanna S. M., Del Toro A., Laychock S. G. (2010) ATP-independent glucose stimulation of sphingosine kinase in rat pancreatic islets. J. Lipid Res. 51, 2171–2180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Pitson S. M., Moretti P. A., Zebol J. R., Lynn H. E., Xia P., Vadas M. A., Wattenberg B. W. (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22, 5491–5500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Hait N. C., Bellamy A., Milstien S., Kordula T., Spiegel S. (2007) Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J. Biol. Chem. 282, 12058–12065 [DOI] [PubMed] [Google Scholar]
  • 38. Ding G., Sonoda H., Yu H., Kajimoto T., Goparaju S. K., Jahangeer S., Okada T., Nakamura S. (2007) Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J. Biol. Chem. 282, 27493–27502 [DOI] [PubMed] [Google Scholar]
  • 39. Mizugishi K., Yamashita T., Olivera A., Miller G. F., Spiegel S., Proia R. L. (2005) Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113–11121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Pappu R., Schwab S. R., Cornelissen I., Pereira J. P., Regard J. B., Xu Y., Camerer E., Zheng Y. W., Huang Y., Cyster J. G., Coughlin S. R. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine 1-phosphate. Science 316, 295–298 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Data
supp_287_16_13457__index.html (1KB, html)
supp_M111.268185_jbc.M111.268185-1.pdf (427.9KB, pdf)

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES